Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
| ▸ | UGCG | Q16739 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9288534 | 0.88 | ADRA1D (0.78) | ADRA1DADRA1AADRA1BKMT2APOLB | |
| SCHEMBL9083597 | 0.87 | ADRA1D (0.77) | ADRA1DADRA1AADRA1BKMT2APOLB | |
| SCHEMBL9082016 | 0.85 | ADRA1D (0.74) | ADRA1DADRA1AADRA1BGRIN2BALDH1A1 | |
| SCHEMBL9082667 | 0.84 | ADRA1D (0.73) | ADRA1DADRA1AADRA1BKMT2APOLB | |
| SCHEMBL4695758 | 0.84 | ADRA1D (0.73) | ADRA1DADRA1AADRA1BKMT2APOLB | |
| SCHEMBL9082550 | 0.83 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BKMT2APOLB | |
| SCHEMBL9082586 | 0.83 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BKMT2APOLB | |
| SCHEMBL9085175 | 0.83 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BKMT2APOLB | |
| SCHEMBL9083412 | 0.82 | ADRA1D (0.70) | ADRA1DADRA1AADRA1BKMT2APOLB | |
| SCHEMBL1966331 | 0.81 | ADRA1D (0.67) | ADRA1DADRA1AADRA1BKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602888-B2 | Binds to a human alpha 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human alpha 1A adrenergic receptor | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-05 | — | — | US | disclosed |
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | H. LUNDBECK A/S (DK) | 2002-03-14 | — | — | US | disclosed |
| US-6015819-A | ADMINISTERING ADRENERGIC BLOCKING AGENT; REDUCTION OF ORTHOSTATIC FALL IN BLOOD PRESSURE SIDE EFFECT; FDA ORANGE BOOK LISTED PATENT FOR SILODOSIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-01-18 | — | — | US | disclosed |
| US-5990128-A | ADMINISTERING AN ANTAGONIST THAT BINDS TO A HUMAN ALPHA-1C ADRENERGIC RECEPTOR WITH A BINDING AFFINITY AT LEAST 691-FOLD HIGHER THAN THE BINDING AFFINITY WITH WHICH THE ANTAGONIST BINDS TO A HUMAN ALPHA-1B ADRENERGIC RECEPTOR | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0758894-A4 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMA CORP (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5780485-A | ADMINISTERING ADRENERGIC BLOCKING AGENT; SIDE EFFECT REDUCTION; FDA ORANGE BOOK LISTED PATENT FOR SILODOSIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0667769-A4 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA. | SYNAPTIC PHARMA CORP (US) | 1998-02-04 | — | — | EP | disclosed |
| EP-0758894-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5578611-A | ANTITUMOR AGENTS AND PROSTATE TUMOR DETECTION BY BINDING HUMAN ALPHA-ADRENERGIC RECEPTOR AND HISTAMINE H1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-11-26 | — | — | US | disclosed |
| US-5508306-A | USED FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE AND INHIBITING CHOLESTEROL SYNTHESIS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995028157-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-10-26 | — | — | WO | disclosed |
| EP-0667769-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995007075-A9 | NOVEL AROMATIC AMINE DERIVATIVES | — | 1995-04-27 | — | — | WO | disclosed |
| US-5403847-A | Administering a therapeutic amount of a compound which binds to a human alpha 1c adrenergic receptor; FDA Orange book listed patent for silodosin | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-04-04 | — | — | US | disclosed |
| WO-1994010989-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | ADRB1, ADRA1B, ADRA1A | ADRA1D 4/4885ADRA1A 3/4885ADRA1B 2/4885 |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | ADRB1, ADRA1B, ADRA1A | ADRA1D 4/4885ADRA1A 3/4885ADRA1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.